Clinical analysis of ovarian preservation for stageⅠendometrial carcinomas in women aged 40 years and younger
10.3760/cma.j.issn.0529-567x.2014.04.005
- VernacularTitle:年龄≤40岁Ⅰ期子宫内膜癌患者保留卵巢的临床分析
- Author:
Lin LI
;
Lingying WU
;
Rong ZHANG
;
Gongyi ZHANG
;
Ning LI
;
Xiaoguang LI
;
Guangwen YUAN
- Publication Type:Journal Article
- Keywords:
Endometrial neoplasms;
Ovary;
Gynecologic surgical procedures;
Prognosis;
Age of onset;
Fertility preservation
- From:
Chinese Journal of Obstetrics and Gynecology
2014;(4):260-264
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the safety of ovarian preservation for stage Ⅰ endometrial carcinomas in women aged 40 years and younger.Methods Seventy-five cases of stage Ⅰ endometrial cancer aged 40 years and younger from Jan 1999 to Jan 2012 were treated in Cancer Hospital , Chinese Academy of Medical Sciences.They were further divided into two groups:20 patients who underwent ovarian preservation (group A) and 55 patients who underwent oophorectomy (group B).Clinical and pathological recordings of these patients were reviewed and compared.Results In the group A , there were 13 patients preserved both ovaries , and 7 patients preserved a single ovary.While there were no significant differences in the age, body mass index, surgical staging, histology, grade, cytology of peritoneal lavage or ascites , and postoperative treatment between two groups ( all P>0.05 ).The differences in the level of CA 125 [ 25%(5/20) versus 18%(10/55)] and number of patients underwent pelvic lymphadenectomy [35% (7/20) versus 84%(46/55)] were statistically significant between two groups (all P<0.05).Of seventy-five cases, only two patients relapsed and all survived after a median follow-up time of 31.7 months ( range:0 to 160 months).Kaplan-Meier analysis revealed no difference in overall survival (100.0% versus 100.0%) and disease free survival ( 90.0% versus 95.5%) between two groups ( P =0.579 ).Conclusions Ovarian preservation has no statistically significant impact on the survival of young patients with stage Ⅰa, well differentiated endometrial cancer.Large-scale, prospective clinical studies are needed to validate the safety of ovarian preservation for those patients.
